首页> 外文期刊>Diabetes >Platelet Hyperreactivity in Diabetes: Focus on GP(Ⅵ) Signaling-Are Useful Drugs Already Available?
【24h】

Platelet Hyperreactivity in Diabetes: Focus on GP(Ⅵ) Signaling-Are Useful Drugs Already Available?

机译:糖尿病患者的血小板反应性过高:关注GP(Ⅵ)信号传导-是否已经有有用的药物?

获取原文
获取原文并翻译 | 示例
       

摘要

Adults with diabetes are 2-4 times more likely to suffer from heart disease or ischemic stroke than adults without diabetes, yet standard antiplatelet therapy, which is the cornerstone for primary and secondary prevention of cardiovascular disease, fails in many patients with diabetes. Three independent but often interrelated variables that contribute to platelet hyperreactivity-high blood glucose, oxidative stress, and elevated vascular shear forces-coexist in patients with diabetes, creating a perilous concurrence of risk factors for cardiovascular events. Recent research has focused attention on the platelet-specific collagen receptor glycoprotein (Ⅵ) (GP(Ⅵ)) as a potential antrthrombotic target. Signaling events downstream of GPVI are influenced by hyperglycemia, oxidative stress, and shear stress. Importantly, drugs targeting these GPVI signaling pathways are already in existence. The potential to repurpose existing drugs is a high-gain strategy for yielding new antiplatelet agents and could have particular benefit in individuals with diabetes.
机译:与没有糖尿病的成年人相比,患有糖尿病的成年人患心脏病或缺血性中风的可能性是未患糖尿病的成年人的2-4倍,而标准的抗血小板治疗是心血管疾病一级和二级预防的基石,但在许多糖尿病患者中却失败了。糖尿病患者并存有三个独立但经常相互关联的变量,这些变量会导致血小板反应过度,即高血糖,氧化应激和血管切变力升高,导致心血管事件危险因素并存。最近的研究集中于血小板特异性胶原受体糖蛋白(Ⅵ)(GP(Ⅵ))作为潜在的血栓形成靶标。 GPVI下游的信号事件受高血糖,氧化应激和剪切应激的影响。重要的是,针对这些GPVI信号通路的药物已经存在。重新利用现有药物的潜力是生产新的抗血小板药物的高收益策略,并且可能对糖尿病患者有特殊益处。

著录项

  • 来源
    《Diabetes》 |2017年第1期|7-13|共7页
  • 作者单位

    Australian Centre for Blood Diseases, Monash University, Melbourne, Australia;

    Baker IDI Heart and Diabetes Institute, Melbourne, Australia;

    Australian Centre for Blood Diseases, Monash University, Melbourne, Australia;

  • 收录信息 美国《科学引文索引》(SCI);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-18 03:46:06

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号